This article was originally published in RAJ Devices
Australia and India invest in biotechnology
You may also be interested in...
With a global supply chain and commercial platform, the Viatris entity to be formed by the merger of Mylan and Pfizer’s Upjohn unit wants to be the partner of choice for mid-sized products overlooked by companies focused on blockbusters.
Ongoing launches, relatively stable market conditions and cost-cutting initiatives are producing record profits from Teva’s European operations, president and CEO Kåre Schultz told delegates to a J.P. Morgan Healthcare Conference.
The recruitment process for the new executive director of the European Medicines Agency seems to be running to schedule.